Explorez tous les épisodes du podcast The Biotech Startups Podcast

Part 3 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI. In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss.

Part 2 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI. In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss.

Part 1 of 4. My guest for this week’s episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors. In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, which he eventually sold to Capsugel Lonza in 2016. Xcelience was a Florida-based CDMO that specialized in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. His extensive expertise in pharma and cell therapy makes for an insightful conversation that founders can learn from.

Part 4 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.

Part 3 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.

Part 2 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Doug is an experienced investor, Corporate Director, and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents, and raised and invested around $4 billion of public and private capital.

Part 1 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.

Part 4 of 4. My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.

Part 3 of 4. My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.

Part 2 of 4. My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.

Part 1 of 4. My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.

Part 4 of 4. My guest for this week’s episode is Shekhar Mitra, former Senior Vice President of Global Innovation and Chief of Innovation at Procter & Gamble and current President and Founder of InnoPreneur, a strategic advisory firm that enables development of innovation capabilities, ideation, and organizational development for Fortune 500 corporations and new ventures. Prior to InnoPreneur, Shekhar spent 29 years at Procter & Gamble where he worked his way up from staff scientist to Senior Vice President of Global Innovation and Chief of Innovation, becoming a part of P&G's top leadership team and a member of the CEO's Global Leadership Council. Shekhar’s time at P&G paints a successful entrepreneurial road map for those looking to learn, grow, and innovate within large corporations.

Part 1 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a company that is looking to use AI to find cures for rare inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI. In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss.

Part 3 of 4. My guest for this week’s episode is Shekhar Mitra, former Senior Vice President of Global Innovation and Chief of Innovation at Procter & Gamble and current President and Founder of InnoPreneur, a strategic advisory firm that enables development of innovation capabilities, ideation, and organizational development for Fortune 500 corporations and new ventures.

Part 2 of 4. My guest for this week’s episode is Shekhar Mitra, former Senior Vice President of Global Innovation and Chief of Innovation at Procter & Gamble and current President and Founder of InnoPreneur, a strategic advisory firm that enables development of innovation capabilities, ideation, and organizational development for Fortune 500 corporations and new ventures. Prior to InnoPreneur, Shekhar spent 29 years at Procter & Gamble where he worked his way up from staff scientist to Senior Vice President of Global Innovation and Chief of Innovation, becoming a part of P&G's top leadership team and a member of the CEO's Global Leadership Council. Shekhar’s time at P&G paints a successful entrepreneurial road map for those looking to learn, grow, and innovate within large corporations.

Part 1 of 4. My guest for this week’s episode is Shekhar Mitra, former Senior Vice President of Global Innovation and Chief of Innovation at Procter & Gamble and current President and Founder of InnoPreneur, a strategic advisory firm that enables development of innovation capabilities, ideation, and organizational development for Fortune 500 corporations and new ventures.

Part 4 of 4. My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.

Part 3 of 4. My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.

Part 2 of 4. My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.

Part 1 of 4. My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.

Part 4 of 4. My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Part 3 of 4. My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Part 2 of 4. My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Jon Chee hosts our latest guest, Barbara Alcaraz Silva, the Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. Barbara brings a wealth of experience as a former researcher, entrepreneur, and industry veteran. She has worked extensively with startups and early-stage ventures. Her scientific background is in Telomeres and DNA Repair research. Prior to her role at J.P. Morgan, Barbara advised biotech and medtech companies at Manos Accelerator, served as a Senior Investment Fellow at Life Science Angels, and co-founded BioChron, an AI-driven biological aging tracking company. Her unique combination of scientific knowledge, business acumen, and investment/finance expertise makes her an invaluable resource for founders in the biotech space.

Part 1 of 4. My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.

Part 4 of 4. My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. He has also been a professor and researcher at Cambridge for more than 15 years. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. The company applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.

Part 3 of 4. My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.

Part 2 of 4. My guest today is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and Founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery and cell therapy. Bit.bio applies a patented safe harbor gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells into highly defined and mature human cell types.

Part 1 of 4. My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.

Part 4 of 4. My guest for this week’s episode is Quin Wills, CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.

Part 3 of 4. My guest for this week’s episode is Quin Wills, CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.

Part 2 of 4. My guest for this week’s episode is Quin Wills, CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.

Part 1 of 4. My guest for this week’s episode is Quin Wills, CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.

Part 3 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform, providing highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals. Their approach starts with novel immobilization engineering for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach their clients' targets for commercialization of their new biochemical production process.

Part 3 of 4. My guest for this week’s episode is Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. Barbara is a former researcher and entrepreneur, and an accomplished industry veteran. Her career has revolved around startups and early-stage ventures. As a graduate student, she focused on Telomeres and DNA Repair. Before joining J.P. Morgan, Barbara was an advisor for biotech and medtech companies at the Manos Accelerator, where she provided mentorship in business development, fundraising, and other key areas. She also served as a Senior Investment Fellow at Life Science Angels, where she invested in emerging biotechs and managed investor relationships. Additionally, Barbara co-founded BioChron, a company that leveraged AI and machine learning to track biological aging.

Part 2 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform, providing highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals. Their approach starts with novel immobilization engineering for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach their clients' targets for commercialization of their new biochemical production process.

Part 1 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform. With clients ranging from startups to multinationals like Sumitomo Chemical Company, FabricNano provides highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals.

Part 3 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Part 2 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Part 1 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health. The Sherlock team and founders include engineering biology pioneers with world-leading expertise in CRISPR and synthetic biology, diagnostic industry veterans, and disease area authorities.

Part 3 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 1 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Vizgen’s technology will aid the acceleration of biological research and discovery to advance human health

Part 3 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science.

Part 2 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 2 of 4. My guest for this week’s episode is Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. She is also a former scientist-entrepreneur whose graduate studies focused on Telomeres and DNA Repair. Barbara has worked with many startups, including co-founding her own company, BioChron. While at the Manos Accelerator, she worked as an advisor for Biotech and Medtech companies, providing mentorship in business, fundraising, and capital, and offering guidance to startup companies. Additionally, Barbara worked as a Senior Investment Fellow at Life Science Angels, investing in up-and-coming biotechs and managing investor relationships.

Part 1 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 3 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 1 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.